1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI).

Authors :: Maso, A. Dal
Ferro, A.
Lorenzi, M.
Polo, V.
Scattolin, D.
Del Conte, A.
Scoccia, E.
Frega, S.
Bonanno, L.
Indraccolo, S.
Calabrese, F.
Guarneri, V.
Conte, P.F.
Pasello, G.
Source :: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS886-S886. 1p.
Publication Year :: 2020

Subjects :: *PROTEIN-tyrosine kinase inhibitors
*NON-small-cell lung carcinoma
*EPIDERMAL growth factor receptors
*SORAFENIB

Full Text Access

Tools